Altimmune director granted 48,800 stock options

Altimmune, Inc. director Teri L. Lawver received a grant of stock options as part of non-employee director compensation.

Rhea-AI Filing Summary

Altimmune, Inc. director Teri L. Lawver received a grant of stock options as part of non-employee director compensation. The award covers 48,800 stock options with an exercise price of $2.82 per share and expires on May 1, 2036.

The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on continued board service. After this grant, the filing shows 48,800 derivative securities held.

Insider Trade Summary

Grant/Award: 48,800 shares

Grant/Award 1 txn

Insider Lawver Teri L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (option to buy)	48,800	$0.00	$0.00

Holdings After Transaction: Stock Options (option to buy) — 48,800 contracts (Direct)

Footnotes (2)

1. F1. The options were granted pursuant to the Company's non-employee director compensation policy.
2. F2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Options granted: 48,800 options Exercise price: $2.82 per share Underlying shares: 48,800 shares +2 more

5 metrics

Options granted 48,800 options Grant to non-employee director Teri L. Lawver

Exercise price $2.82 per share Stock option strike price

Underlying shares 48,800 shares Common stock underlying the options

Expiration date May 1, 2036 Option term end date

Post-transaction derivative holdings 48,800 options Total derivative securities following the grant

Key Terms

non-employee director compensation policy, stock options, vested and exercisable

3 terms

non-employee director compensation policy financial

"The options were granted pursuant to the Company's non-employee director compensation policy."

stock options financial

"The shares underlying the option become vested and exercisable in substantially equal monthly installments."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vested and exercisable financial

"The shares underlying the option become vested and exercisable in substantially equal monthly installments."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Altimmune (ALT) director Teri L. Lawver report on this Form 4?

Teri L. Lawver reported receiving a grant of 48,800 stock options to purchase Altimmune common shares. The options were issued at $2.82 per share as part of the company’s non-employee director compensation policy and represent compensation, not an open-market trade.

What are the key terms of the new Altimmune (ALT) stock options granted?

The grant consists of 48,800 stock options with an exercise price of $2.82 per share and an expiration date of May 1, 2036. These options relate to 48,800 shares of Altimmune common stock and were granted at no upfront purchase price.

How and when do Teri L. Lawver’s Altimmune (ALT) options vest?

The options vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026. Vesting is conditioned on Lawver’s continued service as a non-employee director through each applicable monthly vesting date.

Is this Altimmune (ALT) Form 4 a stock purchase or compensation grant?

This Form 4 reflects a compensation grant, not an open-market stock purchase. The reported transaction is a grant of 48,800 stock options at a $2.82 exercise price, issued under Altimmune’s non-employee director compensation policy, with no cash paid per option at grant.

How many Altimmune (ALT) derivative securities does Teri L. Lawver hold after this grant?

After the reported transaction, the filing shows Lawver holding 48,800 derivative securities consisting of stock options. These options give the right to acquire 48,800 shares of Altimmune common stock at an exercise price of $2.82 per share, subject to vesting.

What role does the compensation policy play in this Altimmune (ALT) option grant?

The Form 4 notes the options were granted under Altimmune’s non-employee director compensation policy. This means the award is part of the standard equity-based compensation structure used to pay outside directors, aligning their interests with shareholders through long-term incentives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lawver Teri L

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MARYLAND 20878

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (option to buy)(1)	$2.82	05/01/2026		A		48,800		(2)	05/01/2036	Common Stock, par value $0.0001	48,800	$0	48,800	D

Explanation of Responses:

1. The options were granted pursuant to the Company's non-employee director compensation policy.

2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Gregory Weaver, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)